Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levamisole added to prednisolone to prevent relapse in children with steroid-sensitive idiopathic nephrotic syndrome
NL-OMON60006Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Idiopathic nephrotic syndrome (INS) and nephrosis comparing Prednisolone + levamisole with Prednisolone + placebo (2 arms). Primary endpoint: Occurrence of relapses within 12 months after first presentation. Started Nov 2024; status: active, not recruiting.
02
Drugs
levamisoleprednisolone
03
Conditions
Idiopathic nephrotic syndrome (INS)nephrosis
Beyond the preview
Go deeper on NL-OMON60006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60006.